Abstract
Background: Parkinson´s Disease (PD) is a chronic, progressive condition, being the second most common neurodegenerative disorder worldwide. The classical features include: bradykinesia, resting tremor, rigidity and festination. These neurological alterations are probably due to the death of dopaminergic neurons in the Substantia Nigra pars compacta and consequent reduction of dopamine input into the striatum. The decrease of dopamine levels may also be involved in the emergence of non-motor symptoms, including cognitive impairment, anxiety and depression symptoms. Neurotrophic Factors (NF) are proteins that modulate neuronal function, development, and survival. It has been reported that NF might exert a protective role in PD.
Objective: We aim to discuss the emerging evidence from pre-clinical and clinical studies regarding the role of NF in PD as well as their potential as promising therapeutic strategies.
Methods: We carried out an extensive literature search in PubMed central.
Results: Pre-clinical studies using NF to treat PD are divergent probably due to several methodological differences, thus precluding any conclusion. Clinical studies findings obtained with the administration of NF in patients with PD were even more disappointed. On the other hand, pre-clinical and clinical studies generally support that physical activity is a low-cost, non-pharmacologic strategy with good results to treat PD.
Conclusion: The use of NF as a treatment for PD is still a promise not incorporated in clinical practice. Methods to deliver NFs, doses and compounds administered, side effects, population characteristics and duration of disease may probably contribute to the unsuccessful results.
Keywords: Parkinson´s disease, neurotrophic factors, BDNF, GDNF, MPTP, 6-OHDA.
Current Medicinal Chemistry
Title:Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Volume: 25 Issue: 31
Author(s): Rodrigo N. Ferreira, Aline S. de Miranda, Natalia P. Rocha, Ana C. Simoes e Silva, Antonio L. Teixeira and Elizabeth R. da Silva Camargos*
Affiliation:
- Laboratorio de Neurobiologia, Departamento de Morfologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte,Brazil
Keywords: Parkinson´s disease, neurotrophic factors, BDNF, GDNF, MPTP, 6-OHDA.
Abstract: Background: Parkinson´s Disease (PD) is a chronic, progressive condition, being the second most common neurodegenerative disorder worldwide. The classical features include: bradykinesia, resting tremor, rigidity and festination. These neurological alterations are probably due to the death of dopaminergic neurons in the Substantia Nigra pars compacta and consequent reduction of dopamine input into the striatum. The decrease of dopamine levels may also be involved in the emergence of non-motor symptoms, including cognitive impairment, anxiety and depression symptoms. Neurotrophic Factors (NF) are proteins that modulate neuronal function, development, and survival. It has been reported that NF might exert a protective role in PD.
Objective: We aim to discuss the emerging evidence from pre-clinical and clinical studies regarding the role of NF in PD as well as their potential as promising therapeutic strategies.
Methods: We carried out an extensive literature search in PubMed central.
Results: Pre-clinical studies using NF to treat PD are divergent probably due to several methodological differences, thus precluding any conclusion. Clinical studies findings obtained with the administration of NF in patients with PD were even more disappointed. On the other hand, pre-clinical and clinical studies generally support that physical activity is a low-cost, non-pharmacologic strategy with good results to treat PD.
Conclusion: The use of NF as a treatment for PD is still a promise not incorporated in clinical practice. Methods to deliver NFs, doses and compounds administered, side effects, population characteristics and duration of disease may probably contribute to the unsuccessful results.
Export Options
About this article
Cite this article as:
Ferreira N. Rodrigo , de Miranda S. Aline , Rocha P. Natalia , Simoes e Silva C. Ana , Teixeira L. Antonio and da Silva Camargos R. Elizabeth *, Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?, Current Medicinal Chemistry 2018; 25 (31) . https://dx.doi.org/10.2174/0929867325666180313101536
DOI https://dx.doi.org/10.2174/0929867325666180313101536 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Microbial Antigenic Pressure and Evolution of the Immune Response: Toward a Better Understanding of the Human Immune System in Health and Disease and Therapeutic Interventions
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?
Current Medicinal Chemistry - Central Nervous System Agents Characterization of the Non-Fibrillar α-Synuclein Oligomers
Protein & Peptide Letters Simple Choline Esters as Potential Anti-Alzheimer Agents
Current Pharmaceutical Design Ethical Implications for Clinical Practice and Future Research in “At Risk” Individuals
Current Pharmaceutical Design Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable
Current Pharmaceutical Design New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics